Links to Exploration step
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">New approaches for the treatment of diabetic macular oedema: recommendations by an expert panel</title><author><name sortKey="Bandello, F" sort="Bandello, F" uniqKey="Bandello F" first="F" last="Bandello">F. Bandello</name><affiliation><nlm:aff id="aff1"><institution>Department of Ophthalmology, University Vita-Salute, Scientific Institute San Raffaele</institution>, Milano,<country>Italy</country></nlm:aff></affiliation></author><author><name sortKey="Cunha Vaz, J" sort="Cunha Vaz, J" uniqKey="Cunha Vaz J" first="J" last="Cunha-Vaz">J. Cunha-Vaz</name><affiliation><nlm:aff id="aff2"><institution>Association for Innovation and Biomedical Research on Light and Image</institution>, Coimbra,<country>Portugal</country></nlm:aff></affiliation></author><author><name sortKey="Chong, N V" sort="Chong, N V" uniqKey="Chong N" first="N V" last="Chong">N V Chong</name><affiliation><nlm:aff id="aff3"><institution>Oxford Eye Hospital, University of Oxford</institution>, Oxford,<country>UK</country></nlm:aff></affiliation></author><author><name sortKey="Lang, G E" sort="Lang, G E" uniqKey="Lang G" first="G E" last="Lang">G E Lang</name><affiliation><nlm:aff id="aff4"><institution>Department of Ophthalmology, University Eye Hospital</institution>, Ulm,<country>Germany</country></nlm:aff></affiliation></author><author><name sortKey="Massin, P" sort="Massin, P" uniqKey="Massin P" first="P" last="Massin">P. Massin</name><affiliation><nlm:aff id="aff5"><institution>Assistance Publique des Hôpitaux de Paris, Ophthalmology Department, Hôpital Lariboisière</institution>, Paris,<country>France</country></nlm:aff></affiliation></author><author><name sortKey="Mitchell, P" sort="Mitchell, P" uniqKey="Mitchell P" first="P" last="Mitchell">P. Mitchell</name><affiliation><nlm:aff id="aff6"><institution>Discipline of Ophthalmology, University of Sydney</institution>, Sydney,<country>Australia</country></nlm:aff></affiliation></author><author><name sortKey="Porta, M" sort="Porta, M" uniqKey="Porta M" first="M" last="Porta">M. Porta</name><affiliation><nlm:aff id="aff7"><institution>Department of Internal Medicine, University of Turin</institution>, Turin,<country>Italy</country></nlm:aff></affiliation></author><author><name sortKey="Prunte, C" sort="Prunte, C" uniqKey="Prunte C" first="C" last="Prünte">C. Prünte</name><affiliation><nlm:aff id="aff8"><institution>Department of Ophthalmology and Optometry, Medical University of Vienna</institution>, Vienna,<country>Austria</country></nlm:aff></affiliation><affiliation><nlm:aff id="aff9"><institution>Vista Klinik</institution>, Binningen,<country>Switzerland</country></nlm:aff></affiliation></author><author><name sortKey="Schlingemann, R" sort="Schlingemann, R" uniqKey="Schlingemann R" first="R" last="Schlingemann">R. Schlingemann</name><affiliation><nlm:aff id="aff10"><institution>Medical Retina Unit and Ocular Angiogenesis Group, Department of Ophthalmology, University of Amsterdam, Academic Medical Centre</institution>, Amsterdam,<country>The Netherlands</country></nlm:aff></affiliation><affiliation><nlm:aff id="aff11"><institution>Department of Clinical and Molecular Ophthalmogenetics, The Netherlands Institute for Neuroscience, Royal Netherlands Academy of Arts and Sciences (KNAW)</institution>, Amsterdam,<country>The Netherlands</country></nlm:aff></affiliation></author><author><name sortKey="Schmidt Erfurth, U" sort="Schmidt Erfurth, U" uniqKey="Schmidt Erfurth U" first="U" last="Schmidt-Erfurth">U. Schmidt-Erfurth</name><affiliation><nlm:aff id="aff8"><institution>Department of Ophthalmology and Optometry, Medical University of Vienna</institution>, Vienna,<country>Austria</country></nlm:aff></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PMC</idno><idno type="pmid">22241014</idno><idno type="pmc">3325561</idno><idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3325561</idno><idno type="RBID">PMC:3325561</idno><idno type="doi">10.1038/eye.2011.337</idno><date when="2012">2012</date><idno type="wicri:Area/Pmc/Corpus">000146</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Corpus" wicri:corpus="PMC">000146</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a" type="main">New approaches for the treatment of diabetic macular oedema: recommendations by an expert panel</title><author><name sortKey="Bandello, F" sort="Bandello, F" uniqKey="Bandello F" first="F" last="Bandello">F. Bandello</name><affiliation><nlm:aff id="aff1"><institution>Department of Ophthalmology, University Vita-Salute, Scientific Institute San Raffaele</institution>, Milano,<country>Italy</country></nlm:aff></affiliation></author><author><name sortKey="Cunha Vaz, J" sort="Cunha Vaz, J" uniqKey="Cunha Vaz J" first="J" last="Cunha-Vaz">J. Cunha-Vaz</name><affiliation><nlm:aff id="aff2"><institution>Association for Innovation and Biomedical Research on Light and Image</institution>, Coimbra,<country>Portugal</country></nlm:aff></affiliation></author><author><name sortKey="Chong, N V" sort="Chong, N V" uniqKey="Chong N" first="N V" last="Chong">N V Chong</name><affiliation><nlm:aff id="aff3"><institution>Oxford Eye Hospital, University of Oxford</institution>, Oxford,<country>UK</country></nlm:aff></affiliation></author><author><name sortKey="Lang, G E" sort="Lang, G E" uniqKey="Lang G" first="G E" last="Lang">G E Lang</name><affiliation><nlm:aff id="aff4"><institution>Department of Ophthalmology, University Eye Hospital</institution>, Ulm,<country>Germany</country></nlm:aff></affiliation></author><author><name sortKey="Massin, P" sort="Massin, P" uniqKey="Massin P" first="P" last="Massin">P. Massin</name><affiliation><nlm:aff id="aff5"><institution>Assistance Publique des Hôpitaux de Paris, Ophthalmology Department, Hôpital Lariboisière</institution>, Paris,<country>France</country></nlm:aff></affiliation></author><author><name sortKey="Mitchell, P" sort="Mitchell, P" uniqKey="Mitchell P" first="P" last="Mitchell">P. Mitchell</name><affiliation><nlm:aff id="aff6"><institution>Discipline of Ophthalmology, University of Sydney</institution>, Sydney,<country>Australia</country></nlm:aff></affiliation></author><author><name sortKey="Porta, M" sort="Porta, M" uniqKey="Porta M" first="M" last="Porta">M. Porta</name><affiliation><nlm:aff id="aff7"><institution>Department of Internal Medicine, University of Turin</institution>, Turin,<country>Italy</country></nlm:aff></affiliation></author><author><name sortKey="Prunte, C" sort="Prunte, C" uniqKey="Prunte C" first="C" last="Prünte">C. Prünte</name><affiliation><nlm:aff id="aff8"><institution>Department of Ophthalmology and Optometry, Medical University of Vienna</institution>, Vienna,<country>Austria</country></nlm:aff></affiliation><affiliation><nlm:aff id="aff9"><institution>Vista Klinik</institution>, Binningen,<country>Switzerland</country></nlm:aff></affiliation></author><author><name sortKey="Schlingemann, R" sort="Schlingemann, R" uniqKey="Schlingemann R" first="R" last="Schlingemann">R. Schlingemann</name><affiliation><nlm:aff id="aff10"><institution>Medical Retina Unit and Ocular Angiogenesis Group, Department of Ophthalmology, University of Amsterdam, Academic Medical Centre</institution>, Amsterdam,<country>The Netherlands</country></nlm:aff></affiliation><affiliation><nlm:aff id="aff11"><institution>Department of Clinical and Molecular Ophthalmogenetics, The Netherlands Institute for Neuroscience, Royal Netherlands Academy of Arts and Sciences (KNAW)</institution>, Amsterdam,<country>The Netherlands</country></nlm:aff></affiliation></author><author><name sortKey="Schmidt Erfurth, U" sort="Schmidt Erfurth, U" uniqKey="Schmidt Erfurth U" first="U" last="Schmidt-Erfurth">U. Schmidt-Erfurth</name><affiliation><nlm:aff id="aff8"><institution>Department of Ophthalmology and Optometry, Medical University of Vienna</institution>, Vienna,<country>Austria</country></nlm:aff></affiliation></author></analytic><series><title level="j">Eye</title><idno type="ISSN">0950-222X</idno><idno type="eISSN">1476-5454</idno><imprint><date when="2012">2012</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en"><p>The current standard therapy for patients with diabetic macular oedema (DME)—focal/grid laser photocoagulation—usually does not improve impaired vision, and many patients lose vision despite laser therapy. Recent approval of ranibizumab by the European Medicines Agency to treat visual impairment due to DME fulfils the previously unmet medical need for a treatment that can improve visual acuity (VA) in these patients. We reviewed 1- and 2-year clinical trial findings for ranibizumab used as treatment for DME to formulate evidence-based treatment recommendations in the context of this new therapy. DME with or without visual impairment should be considered for treatment when it fulfils the Early Treatment Diabetic Retinopathy Study (ETDRS) criteria for clinically significant oedema. For DME with centre involvement and associated vision loss due to DME, monthly ranibizumab monotherapy with treatment interruption and re-initiation based on VA stability is recommended. Laser therapy based on ETDRS guidelines is recommended for other forms of clinically significant DME without centre involvement or when no vision loss has occurred, despite centre involvement. Because these recommendations are based on randomised controlled trials of 1–2 years duration, guidance may need updating as long-term ranibizumab data become available and as additional therapeutic agents are assessed in clinical trials.</p></div></front></TEI><pmc article-type="review-article"><pmc-comment>The publisher of this article does not allow downloading of the full text in XML form.</pmc-comment>
<front><journal-meta><journal-id journal-id-type="nlm-ta">Eye (Lond)</journal-id><journal-id journal-id-type="iso-abbrev">Eye (Lond)</journal-id><journal-title-group><journal-title>Eye</journal-title></journal-title-group><issn pub-type="ppub">0950-222X</issn><issn pub-type="epub">1476-5454</issn><publisher><publisher-name>Nature Publishing Group</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">22241014</article-id><article-id pub-id-type="pmc">3325561</article-id><article-id pub-id-type="pii">eye2011337</article-id><article-id pub-id-type="doi">10.1038/eye.2011.337</article-id><article-categories><subj-group subj-group-type="heading"><subject>Review</subject></subj-group></article-categories><title-group><article-title>New approaches for the treatment of diabetic macular oedema: recommendations by an expert panel</article-title><alt-title alt-title-type="running">Treatment recommendations for DME</alt-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Bandello</surname><given-names>F</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Cunha-Vaz</surname><given-names>J</given-names></name><xref ref-type="aff" rid="aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Chong</surname><given-names>N V</given-names></name><xref ref-type="aff" rid="aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Lang</surname><given-names>G E</given-names></name><xref ref-type="aff" rid="aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Massin</surname><given-names>P</given-names></name><xref ref-type="aff" rid="aff5">5</xref></contrib><contrib contrib-type="author"><name><surname>Mitchell</surname><given-names>P</given-names></name><xref ref-type="aff" rid="aff6">6</xref></contrib><contrib contrib-type="author"><name><surname>Porta</surname><given-names>M</given-names></name><xref ref-type="aff" rid="aff7">7</xref></contrib><contrib contrib-type="author"><name><surname>Prünte</surname><given-names>C</given-names></name><xref ref-type="aff" rid="aff8">8</xref><xref ref-type="aff" rid="aff9">9</xref></contrib><contrib contrib-type="author"><name><surname>Schlingemann</surname><given-names>R</given-names></name><xref ref-type="aff" rid="aff10">10</xref><xref ref-type="aff" rid="aff11">11</xref></contrib><contrib contrib-type="author"><name><surname>Schmidt-Erfurth</surname><given-names>U</given-names></name><xref ref-type="aff" rid="aff8">8</xref><xref ref-type="corresp" rid="caf1">*</xref></contrib><aff id="aff1"><label>1</label><institution>Department of Ophthalmology, University Vita-Salute, Scientific Institute San Raffaele</institution>, Milano,<country>Italy</country></aff><aff id="aff2"><label>2</label><institution>Association for Innovation and Biomedical Research on Light and Image</institution>, Coimbra,<country>Portugal</country></aff><aff id="aff3"><label>3</label><institution>Oxford Eye Hospital, University of Oxford</institution>, Oxford,<country>UK</country></aff><aff id="aff4"><label>4</label><institution>Department of Ophthalmology, University Eye Hospital</institution>, Ulm,<country>Germany</country></aff><aff id="aff5"><label>5</label><institution>Assistance Publique des Hôpitaux de Paris, Ophthalmology Department, Hôpital Lariboisière</institution>, Paris,<country>France</country></aff><aff id="aff6"><label>6</label><institution>Discipline of Ophthalmology, University of Sydney</institution>, Sydney,<country>Australia</country></aff><aff id="aff7"><label>7</label><institution>Department of Internal Medicine, University of Turin</institution>, Turin,<country>Italy</country></aff><aff id="aff8"><label>8</label><institution>Department of Ophthalmology and Optometry, Medical University of Vienna</institution>, Vienna,<country>Austria</country></aff><aff id="aff9"><label>9</label><institution>Vista Klinik</institution>, Binningen,<country>Switzerland</country></aff><aff id="aff10"><label>10</label><institution>Medical Retina Unit and Ocular Angiogenesis Group, Department of Ophthalmology, University of Amsterdam, Academic Medical Centre</institution>, Amsterdam,<country>The Netherlands</country></aff><aff id="aff11"><label>11</label><institution>Department of Clinical and Molecular Ophthalmogenetics, The Netherlands Institute for Neuroscience, Royal Netherlands Academy of Arts and Sciences (KNAW)</institution>, Amsterdam,<country>The Netherlands</country></aff></contrib-group><author-notes><corresp id="caf1"><label>*</label><institution>Medical University of Vienna, Department of Ophthalmology and Optometry</institution>, Waehringer Guertel 18-20, Vienna 1090, <country>Austria</country>. Tel: +43 1 40400 7941; Fax: +43 1 40400 7912. E-mail: <email>ursula.schmidt-erfurth@meduniwien.ac.at</email></corresp></author-notes><pub-date pub-type="ppub"><month>04</month><year>2012</year></pub-date><pub-date pub-type="epub"><day>13</day><month>01</month><year>2012</year></pub-date><volume>26</volume><issue>4</issue><fpage>485</fpage><lpage>493</lpage><history><date date-type="received"><day>22</day><month>08</month><year>2011</year></date><date date-type="accepted"><day>10</day><month>11</month><year>2011</year></date></history><permissions><copyright-statement>Copyright © 2012 Royal College of Ophthalmologists</copyright-statement><copyright-year>2012</copyright-year><copyright-holder>Royal College of Ophthalmologists</copyright-holder></permissions><abstract><p>The current standard therapy for patients with diabetic macular oedema (DME)—focal/grid laser photocoagulation—usually does not improve impaired vision, and many patients lose vision despite laser therapy. Recent approval of ranibizumab by the European Medicines Agency to treat visual impairment due to DME fulfils the previously unmet medical need for a treatment that can improve visual acuity (VA) in these patients. We reviewed 1- and 2-year clinical trial findings for ranibizumab used as treatment for DME to formulate evidence-based treatment recommendations in the context of this new therapy. DME with or without visual impairment should be considered for treatment when it fulfils the Early Treatment Diabetic Retinopathy Study (ETDRS) criteria for clinically significant oedema. For DME with centre involvement and associated vision loss due to DME, monthly ranibizumab monotherapy with treatment interruption and re-initiation based on VA stability is recommended. Laser therapy based on ETDRS guidelines is recommended for other forms of clinically significant DME without centre involvement or when no vision loss has occurred, despite centre involvement. Because these recommendations are based on randomised controlled trials of 1–2 years duration, guidance may need updating as long-term ranibizumab data become available and as additional therapeutic agents are assessed in clinical trials.</p></abstract><kwd-group><kwd>diabetic retinopathy</kwd><kwd>expert recommendations</kwd><kwd>vascular endothelial growth factor inhibitors</kwd></kwd-group></article-meta></front></pmc></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/Pmc/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 0001469 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Pmc/Corpus/biblio.hfd -nk 0001469 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Asie
|area= AustralieFrV1
|flux= Pmc
|étape= Corpus
|type= RBID
|clé=
|texte=
}}
| This area was generated with Dilib version V0.6.33. |  |